Results 21 to 30 of about 1,273,410 (345)

Increased survival with enzalutamide in prostate cancer after chemotherapy.

New England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. de Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. D. de Bono   +19 more
semanticscholar   +1 more source

Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes

BMC Urology, 2022
Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker   +11 more
doaj   +1 more source

Abiraterone and increased survival in metastatic prostate cancer.

New England Journal of Medicine, 2011
BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with ...
J. D. de Bono, C. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K. Chi, Robert J. Jones, O. Goodman, F. Saad, J. Staffurth, P. Mainwaring, S. Harland, T. Flaig, Thomas E. Hutson, T. Cheng, H. Patterson, J. Hainsworth, C. Ryan, C. Sternberg, S. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C. Haqq, H. Scher   +31 more
semanticscholar   +1 more source

Screening and prostate-cancer mortality in a randomized European study.

New England Journal of Medicine, 2009
BACKGROUND The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer.
F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, H. Lilja, M. Zappa, L. Denis, F. Recker, A. Berenguer, L. Määttänen, C. Bangma, G. Aus, A. Villers, X. Rébillard, T. H. van der Kwast, B. G. Blijenberg, S. Moss, H. D. de Koning, A. Auvinen   +22 more
semanticscholar   +1 more source

Epidemiology of Prostate Cancer

World Journal of Oncology, 2019
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance ...
Prashanth Rawla
semanticscholar   +1 more source

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP   +16 more
doaj   +1 more source

Cloning of a novel receptor expressed in rat prostate and ovary.

Proceedings of the National Academy of Sciences of the United States of America, 1996
We have cloned a novel member of the nuclear receptor superfamily. The cDNA of clone 29 was isolated from a rat prostate cDNA library and it encodes a protein of 485 amino acid residues with a calculated molecular weight of 54.2 kDa.
G. Kuiper, E. Enmark, M. Pelto-huikko, S. Nilsson, J. Gustafsson   +4 more
semanticscholar   +1 more source

PROSTATITIS. [PDF]

JAMA: The Journal of the American Medical Association, 1903
n ...
openaire   +2 more sources

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

npj Precision Oncology, 2023
Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predict DDR deficiency or treatment benefit ...
Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. Chi, Alexander W. Wyatt   +14 more
doaj   +1 more source

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2019
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate
J. Mohler, E. Antonarakis, A. Armstrong, A. D'Amico, B. Davis, T. Dorff, J. Eastham, C. Enke, T. Farrington, C. Higano, E. Horwitz, M. Hurwitz, J. Ippolito, C. Kane, M. Kuettel, J. Lang, J. McKenney, G. Netto, D. Penson, E. Plimack, J. Pow-Sang, T. Pugh, Sylvia S. Richey, M. Roach, Stan Rosenfeld, E. Schaeffer, A. Shabsigh, E. Small, D. Spratt, S. Srinivas, J. Tward, Dorothy Shead, Deborah A. Freedman-Cass   +32 more
semanticscholar   +1 more source